Paper40540751
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.
Andricovich J and 2 others. Blood, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors. Papers, record 40540751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40540751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ubiquitin Thiolesterase | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Mutation | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Mice, Knockout | |
| Gene Expression Regulation, Leukemic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA222930 | NCI NIH HHS | United States | R01CA222930 | PubMed |
Source NIH RePORTER
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 40965944 | BAP1/TP53 loss defines a BCL-xL-dependent erythroleukemia. | https://conductscience.org/library/papers/40965944 |
Source PubMed
References82
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35688146 | Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. | Cell | 2022 | https://conductscience.org/library/papers/35688146 | PubMed |
| 2 | 38458202 | H2AK119ub1 differentially fine-tunes gene expression by modulating canonical PRC1- and H1-dependent chromatin compaction. | Mol Cell | 2024 | https://conductscience.org/library/papers/38458202 | PubMed |
| 3 | 10783170 | Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. | Genes Dev | 2000 | https://conductscience.org/library/papers/10783170 | PubMed |
| 4 | 29113963 | Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. | Blood | 2018 | https://conductscience.org/library/papers/29113963 | PubMed |
| 5 | 8976389 | 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia. | Cytogenet Cell Genet | 1996 | https://conductscience.org/library/papers/8976389 | PubMed |
| 6 | 23827712 | SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. | Cell Stem Cell | 2013 | https://conductscience.org/library/papers/23827712 | PubMed |
| 7 | 35868306 | Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. | Cancer Cell | 2022 | https://conductscience.org/library/papers/35868306 | PubMed |
| 8 | 22878500 | Loss of the tumor suppressor BAP1 causes myeloid transformation. | Science | 2012 | https://conductscience.org/library/papers/22878500 | PubMed |
| 9 | 8329702 | Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. | Blood | 1993 | https://conductscience.org/library/papers/8329702 | PubMed |
| 10 | 26437366 | Loss of BAP1 function leads to EZH2-dependent transformation. | Nat Med | 2015 | https://conductscience.org/library/papers/26437366 | PubMed |
| 11 | 1552940 | Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. | Nature | 1992 | https://conductscience.org/library/papers/1552940 | PubMed |
| 12 | 38849395 | ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers. | Nat Commun | 2024 | https://conductscience.org/library/papers/38849395 | PubMed |
| 13 | 25313317 | Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. | ACS Med Chem Lett | 2014 | https://conductscience.org/library/papers/25313317 | PubMed |
| 14 | 33888563 | BAP1 constrains pervasive H2AK119ub1 to control the transcriptional potential of the genome. | Genes Dev | 2021 | https://conductscience.org/library/papers/33888563 | PubMed |
| 15 | 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732831 | PubMed |
| 16 | 29622463 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29622463 | PubMed |
| 17 | 18371378 | Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. | Cell Stem Cell | 2007 | https://conductscience.org/library/papers/18371378 | PubMed |
| 18 | 35273156 | Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. | Nat Commun | 2022 | https://conductscience.org/library/papers/35273156 | PubMed |
| 19 | 24894717 | Germline mutations in BAP1 impair its function in DNA double-strand break repair. | Cancer Res | 2014 | https://conductscience.org/library/papers/24894717 | PubMed |
| 20 | 30472158 | IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation. | Cell Stem Cell | 2019 | https://conductscience.org/library/papers/30472158 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42499709 | Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42499709 | PubMed |
| 42295372 | BAP1 loss impairs IFN-γ signaling and enhances NK cell-mediated cytotoxicity in myeloid leukemia. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42295372 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAP1 | 8314 | PubTator's text mining | https://conductscience.org/library/genes/8314 | NCBI Gene |
| BCL2L1 | 598 | PubTator's text mining | https://conductscience.org/library/genes/598 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40540751
GET https://conductscience.org/api/papers/v1/40540751/references?page=2